Charles River Labs Buys Second Gene Therapy Company
- Posted by ISPE Boston
- On May 20, 2021
Charles River Laboratories has announced plans to acquire Vigene Biosciences, a Maryland-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The purchase price is expected to be $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5 […]
Read More